AETHLON MEDICAL INC
Business
Aethlon Medical is a clinical-stage medical device company developing the Hemopurifier, a lectin-based extracorporeal immunotherapeutic device designed to remove enveloped viruses and extracellular vesicles from blood plasma. The device is being evaluated in human clinical trials for advanced cancer unresponsive to immunotherapy and life-threatening viral infections. Aethlon currently operates a single ongoing oncology trial in Australia and maintains exploratory programs in viral indications and additional disease states through pre-clinical research.
Summary from 10-K filed 2026-06-10
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2026 2026-03-31 | FY 2025 2025-03-31 | FY 2024 2024-03-31 | FY 2023 2023-03-31 | FY 2022 2022-03-31 |
|---|---|---|---|---|---|---|
| Professional fees | 2 | 2 | 4 | 4 | 3 | |
| Payroll and related expenses | 3 | 4 | 5 | 4 | 5 | |
| General and administrative | 3 | 3 | 4 | 4 | 3 | |
| Total operating expenses | 7 | 9 | 13 | 12 | 11 | |
| OPERATING LOSS | −7 | −9 | −13 | −12 | −10 | |
| Interest income | 156,534 | 298,122 | — | — | — | |
| Other income | 0 | 324,450 | 0 | — | — | |
| Interest expense | −14,372 | −10,109 | — | — | — | |
| Other expense | 0 | −5 | 18,962 | — | — | |
| Total other income (expense), net | 142,162 | −4 | — | — | — | |
| NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | −7 | −13 | −12 | −12 | −10 | |
| Basic net loss per share attributable to common stockholders | −10.61 | −85.77 | −38.87 | −5.86 | −0.71 | |
| Diluted net loss per share attributable to common stockholders | −10.61 | −85.77 | −38.87 | −5.86 | −0.71 | |
| Weighted average number of common shares outstanding - basic | 673,945 | 156,085 | 314,097 | 2 | 15 | |
| Weighted average number of common shares outstanding - diluted | 673,945 | 156,085 | 314,097 | 2 | 15 | |
| OTHER COMPREHENSIVE LOSS | −15,570 | −10,193 | −799 | — | — | |
| COMPREHENSIVE LOSS | −7 | −13 | −12 | −12 | −10 |
Consolidated Balance Sheet
| Concept | Trend | FY 2026 2026-03-31 | FY 2025 2025-03-31 | FY 2024 2024-03-31 | FY 2023 2023-03-31 | FY 2022 2022-03-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 5 | 6 | 5 | 15 | 17 | |
| Deferred offering costs | 210,985 | 0 | 277,827 | 0 | — | |
| Prepaid expenses and other current assets | 332,094 | 448,539 | 505,983 | 557,623 | 956,623 | |
| TOTAL CURRENT ASSETS | 6 | 6 | 6 | 15 | 18 | |
| Property and equipment, net | 356,822 | 676,220 | 1 | 1 | 441,238 | |
| Operating lease right-of-use asset, net | 307,820 | 601,846 | 883,054 | 1 | 696,698 | |
| Patents, net | 0 | 550 | 1,100 | 1,650 | 2,200 | |
| Restricted cash | 98,928 | 97,813 | — | — | — | |
| Deposits | 0 | 33,305 | 33,305 | 33,305 | 33,305 | |
| TOTAL ASSETS | 6 | 7 | 8 | 18 | 19 | |
| Accounts payable | 384,550 | 534,524 | 777,862 | 432,889 | 499,962 | |
| Due to related parties | 68,250 | 579,565 | 546,434 | 214,221 | — | |
| Operating lease liability, current portion | 336,718 | 313,033 | 290,565 | 269,386 | 126,905 | |
| Other current liabilities | 657,317 | 472,164 | 215,038 | 588,592 | 696,893 | |
| TOTAL CURRENT LIABILITIES | 1 | 2 | 2 | 2 | 2 | |
| Operating lease liability, less current portion | 0 | 336,718 | 649,751 | 939,642 | 602,505 | |
| TOTAL LIABILITIES | 1 | 2 | 2 | 2 | 2 | |
| COMMITMENTS AND CONTINGENCIES (Note 8) | — | — | — | — | — | |
| Common stock, $0.001 par value, 100,000,000 shares authorized at March 31, 2026 and 6,000,000 shares authorized at March 31, 2025; 1,570,449 issued and outstanding at March 31, 2026 and 258,531 shares issued and 201,074 outstanding at March 31, 2025 | 1,570 | 259 | 329 | 2,299 | 15,421 | |
| Additional paid-in capital | 180 | 173 | 160 | 157 | 147 | |
| Accumulated other comprehensive loss | −32,703 | −17,133 | −6,940 | −6,141 | 0 | |
| Accumulated deficit | −175 | −168 | −155 | −142 | −130 | |
| TOTAL STOCKHOLDERS EQUITY | 5 | 5 | 6 | 15 | 17 | |
| TOTAL LIABILITIES AND STOCKHOLDERS EQUITY | 6 | 7 | 8 | 18 | 19 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2026 2026-03-31 | FY 2025 2025-03-31 | FY 2024 2024-03-31 | FY 2023 2023-03-31 | FY 2022 2022-03-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 323,653 | 339,559 | 359,057 | 240,892 | 123,685 | |
| Stock-based compensation | 278,547 | 415,234 | 1 | 1 | 750,621 | |
| Non-cash lease expense | 294,026 | 281,208 | 143 | 24,408 | — | |
| Warrant Inducement Expense | 0 | 5 | 0 | — | — | |
| Prepaid expenses and other current assets | 151,550 | 113,923 | −10,232 | 398,169 | −636,688 | |
| Accounts payable and other current liabilities | −383,384 | −53,360 | 156,678 | −174,727 | 97,541 | |
| Due to related parties | −511,315 | 33,131 | 332,213 | 58,479 | 37,222 | |
| Net cash used in operating activities | −7 | −8 | −10 | −11 | −10 | |
| Purchases of property and equipment | −3,704 | 0 | −250,867 | −943,109 | −349,193 | |
| Cash used in investing activities | −3,704 | 0 | −250,867 | −943,109 | −349,193 | |
| Tax withholding payments or tax equivalent payments for net share settlement of restricted stock units | −10,915 | −18,927 | −34,778 | −12,493 | −88,118 | |
| Gross proceeds from the issuance of common stock and pre-funded warrants | 7 | 5 | 1 | 9 | — | |
| Payments for offering costs related to equity issuance | −1 | −1 | — | — | — | |
| Proceeds from exercise of warrants standard terms | 0 | 2 | 0 | — | — | |
| Proceeds from exercise of warrants induced terms | 848,537 | 2 | — | — | — | |
| Commission paid related to warrant inducement | 0 | −153,979 | 0 | — | — | |
| Legal fees paid related to warrant inducement | 0 | −10,877 | — | — | — | |
| Payments for deferred offering costs related to future equity issuance | −129,329 | 0 | — | — | — | |
| Net cash provided by financing activities | 7 | 8 | 1 | 9 | 17 | |
| Effect of Exchange Rate on Changes on Cash | 6,504 | −12,262 | 2,107 | −5,957 | 0 | |
| Net (decrease) increase in cash and cash equivalents and restricted cash | −473,688 | 69,590 | −9 | −3 | 7 | |
| Issuance of shares under vested restricted stock units, net stock option exercises and unvested share issuance for services | 5 | 13 | — | 0 | 676 | |
| Disposal of fully depreciated property | 14,628 | 350,670 | 0 | — | — | |
| Warrant modification costs | 135,676 | 0 | — | — | — | |
| Deferred offering costs not yet paid | 81,656 | 0 | 219,117 | 0 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is AETHLON MEDICAL INC's CIK number?
AETHLON MEDICAL INC's SEC CIK number is 0000882291 (882291). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find AETHLON MEDICAL INC's SEC filings?
All of AETHLON MEDICAL INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did AETHLON MEDICAL INC last report earnings?
AETHLON MEDICAL INC (AEMD) most recently filed an earnings 8-K with the SEC on Jun 10, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001683168-26-004707). This is AETHLON MEDICAL INC's most recent earnings filing of record — not a forecast of its next earnings date.
What is AETHLON MEDICAL INC's most recent earnings 8-K?
AETHLON MEDICAL INC's latest earnings 8-K (Item 2.02) was filed Jun 10, 2026 under accession 0001683168-26-004707. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View AETHLON MEDICAL INC's latest earnings 8-K →
Look up any company's CIK number →